Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$76.4 - $96.33 $679,960 - $857,337
-8,900 Reduced 80.18%
2,200 $207,000
Q4 2023

Feb 14, 2024

BUY
$59.53 - $85.11 $660,783 - $944,721
11,100 New
11,100 $882,000
Q2 2023

Aug 14, 2023

BUY
$45.44 - $71.21 $172,672 - $270,598
3,800 New
3,800 $270,000
Q3 2022

Nov 14, 2022

BUY
$46.84 - $58.49 $182,254 - $227,584
3,891 New
3,891 $207,000
Q4 2021

Feb 14, 2022

SELL
$40.27 - $56.99 $855,737 - $1.21 Million
-21,250 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$47.43 - $84.23 $858,483 - $1.52 Million
18,100 Added 574.6%
21,250 $1.02 Million
Q2 2021

Aug 16, 2021

BUY
$73.06 - $97.7 $230,139 - $307,755
3,150 New
3,150 $267,000
Q3 2020

Nov 16, 2020

SELL
$37.23 - $50.97 $502,158 - $687,483
-13,488 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$28.78 - $46.83 $388,184 - $631,643
13,488 New
13,488 $518,000
Q1 2020

May 15, 2020

SELL
$25.53 - $70.14 $263,571 - $724,125
-10,324 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$54.18 - $65.64 $559,354 - $677,667
10,324 New
10,324 $562,000
Q3 2019

Nov 14, 2019

SELL
$58.58 - $83.91 $1.06 Million - $1.52 Million
-18,100 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$63.59 - $78.71 $483,284 - $598,196
7,600 Added 72.38%
18,100 $1.37 Million
Q1 2019

May 15, 2019

BUY
$50.75 - $80.54 $187,775 - $297,998
3,700 Added 54.41%
10,500 $823,000
Q4 2018

Feb 14, 2019

SELL
$52.18 - $67.93 $121,109 - $157,665
-2,321 Reduced 25.45%
6,800 $382,000
Q3 2018

Nov 14, 2018

SELL
$38.13 - $68.37 $541,446 - $970,854
-14,200 Reduced 60.89%
9,121 $592,000
Q2 2018

Aug 14, 2018

BUY
$27.62 - $44.51 $262,390 - $422,845
9,500 Added 68.74%
23,321 $948,000
Q1 2018

May 15, 2018

SELL
$26.05 - $34.5 $624,210 - $826,689
-23,962 Reduced 63.42%
13,821 $426,000
Q4 2017

Feb 14, 2018

BUY
$24.5 - $36.01 $925,683 - $1.36 Million
37,783
37,783 $969,000

Others Institutions Holding GKOS

About GLAUKOS Corp


  • Ticker GKOS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 47,596,900
  • Market Cap $7.45B
  • Description
  • Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...
More about GKOS
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.